JAMP PILOCARPINE TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

PILOCARPINE HYDROCHLORIDE

Prieinama:

JAMP PHARMA CORPORATION

ATC kodas:

N07AX01

INN (Tarptautinis Pavadinimas):

PILOCARPINE

Dozė:

5MG

Vaisto forma:

TABLET

Sudėtis:

PILOCARPINE HYDROCHLORIDE 5MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Prescription

Gydymo sritis:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0107358009; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2020-12-10

Prekės savybės

_JAMP Pilocarpine Product Monograph_
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
JAMP PILOCARPINE
PILOCARPINE HYDROCHLORIDE TABLETS, USP
5 MG
CHOLINOMIMETIC AGENT
JAMP Pharma Corporation
1310, rue Nobel
Boucherville, Québec
J4B 5H3
Date of Preparation:
December 09, 2020
Submission Control No: 234963
_JAMP Pilocarpine Product Monograph_
_Page 2 of 32_
Table of Contents
PA RT I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
..................................................................................................
6
DRUG INTERACTIONS
................................................................................................
11
DOSAGE AND ADMINISTRATION
................................................................................
11
OVERDOSAGE
.............................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 13
STORAGE AND STABILITY
..........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 18
PART II: SCIENTIFIC INFORMATION
.....................................................................................
19
PHARMACEUTICAL INFORMATION
............................................................................
19
CLINICAL TRIALS
.........................................................................................................